Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever

Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever

Business Wire

Published

SAN DIEGO--(BUSINESS WIRE)--Primmune Therapeutics announces the receipt of a $22.5 million grant from the Defense Threat Reduction Agency to develop a treatment for Lassa fever.

Full Article